Clinical trial · Observational
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer. No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer (Adenocarcinoma) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
| Prostate Cancer (Diagnosis) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
| Prostate Cancer (Post Prostatectomy) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
| Prostate Specific Antigen | — | UNRESOLVED | — |
| Radical Prostatectomy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radical Prostatectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Non-persistent PSA group
- description
- Patients after radical prostatectomy with first postoperative prostate-specific antigen value of \<0.1 ng/ml 4-8 weeks after radical prostatectomy.
- interventionNames
- Procedure: Radical Prostatectomy
- label
- Persistent PSA group
- description
- Patients after radical prostatectomy with first postoperative prostate-specific antigen value of ≥0.1 ng/ml 4-8 weeks after radical prostatectomy.
- interventionNames
- Procedure: Radical Prostatectomy
Primary outcomes (4)
- measure
- Impact of PSA Persistence on Metastasis-Free Survival (MFS)
- timeFrame
- Up to 10 years after radical prostatectomy.
- description
- Comparison of metastasis-free survival between patients with and without PSA persistence.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is an adult biological male. * Patient has morphologically confirmed and untreated prostate cancer. * Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy. * Patient is informed about this observational study and has signed the informed consent form. Exclusion Criteria: * Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation. * Patient received neoadjuvant prostate cancer treatment. * Patient is set to receive adjuvant treatment. * Patient has any contraindications for the operation.
References
Publications (0)
Data not yet available